Neogen Corporation (NEOG) SEC Filings & Earnings Calls
EquiReason read 13 Neogen Corporation SEC filings in the last 12 months. Latest: 10-Q on 2026-10-07 — Neogen reported Q1 FY2027 revenue of $222.8M (+6.5% YoY) and gross margin improvement to 47.4%, but a net loss of $11.9M due to absence of prior year gain on sale..
Source: SEC EDGAR filings · figures as of 2026-08-31 · read by EquiReason
- Market cap
- 2.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 6 Jan, in 74 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
7 Oct 202610-QNeogen reported Q1 FY2027 revenue of $222.8M (+6.5% YoY) and gross margin improvement to 47.4%, but a net loss of $11.9M due to absence of prior year gain on sale.earningsopen
Figures in the filing · each found in the filing text
| Total Revenues · Q1-2027 | $223M | +7% y/y |
| Gross Profit · Q1-2027 | $106M | +11% y/y |
| Gross Margin · Q1-2027 | 47.4% | |
| Operating Loss · Q1-2027 | $-2M | -89% y/y |
| Net (Loss) Income · Q1-2027 | $-12M | -133% y/y |
| Food Safety Revenue · Food Safety · Q1-2027 | $163M | +7% y/y |
| Animal Safety Revenue · Animal Safety · Q1-2027 | $60M | +4% y/y |
| Food Safety Operating Income · Food Safety · Q1-2027 | $16M | +126% y/y |
| Animal Safety Operating Income · Animal Safety · Q1-2027 | $8M | +67% y/y |
| Service Revenue · Q1-2027 | $27M | +7% y/y |
Risks flagged
Tariff and Trade Policy Risk
“With a change in administration in fiscal year 2025, there has been an economic policy shift towards increasing tariffs, which in turn has led and could lead to further retaliatory tariffs. These have increased and may continue to increase our costs on materials imported into the U.S. and have also increased costs and negatively impacted sales from our inter”
Production Inefficiencies Risk
“These production inefficiencies continued throughout fiscal year 2026 and the first quarter of fiscal year 2027, albeit with continued improvement in each successive quarter.” · word for word
Regulatory Approval Risk for Divestiture
“In July 2026, the Australian Competition and Consumer Commission (ACCC) and the New Zealand Commerce Commission (NZCC) each announced that they are moving their respective reviews of the Company’s proposed genomics divestiture into the second phase of review.” · word for word
Inventory Write-off Risk
“In fiscal years 2025 and 2026, we experienced an elevated amount of inventory write-offs, due, in part, to expiration of certain inventory held at our international locations stemming from supply chain and distribution challenges in fiscal year 2024.” · word for word
6 Oct 20268-K · 2.02Q1 FY2027 revenue $222.8M (+6.5% YoY, core +8.1%), adjusted EBITDA $41.6M (+17% YoY), adjusted EPS $0.08 (vs $0.04). Gross margin improved to 47.4%. Full-year guidance raised: revenue $885-890M, adjusted EBITDA $181-183M.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2027 | $223M | +7% y/y |
| Adjusted EBITDA · Q1-2027 | $42M | +17% y/y |
| Adjusted EPS · Q1-2027 | $0.08 | +100% y/y |
| Gross Margin · Q1-2027 | 47.4% | |
| Adjusted Gross Margin · Q1-2027 | 49.8% | |
| Adjusted EBITDA Margin · Q1-2027 | 18.7% | |
| Food Safety Revenue · Food Safety · Q1-2027 | $163M | +7% y/y |
| Animal Safety Revenue · Animal Safety · Q1-2027 | $60M | +4% y/y |
| Net Loss · Q1-2027 | $-12M | |
| Adjusted Net Income · Q1-2027 | $18M | +84% y/y |
Guidance
FY27 revenue raised to $885-890M; Adjusted EBITDA raised to $181-183M.
Full-year FY2027 guidance raised for revenue and Adjusted EBITDA, driven by strong core growth and margin improvement.
Risks flagged
Net loss of $11.9M due to prior-year gain on divestiture; adjusted metrics show improvement.
“Net loss of $11.9 million compared to net income of $36.3 million in prior year due to non-cash gain on divestiture.”
21 Aug 2026DEF 14AProxy statement detailing complete executive leadership transformation, new compensation structure with PSUs, and improved financial performance.open
Figures in the filing · each found in the filing text
| Revenue · FY2026 | $870M | -3% y/y |
| Adjusted EBITDA · FY2026 | $178M | -4% y/y |
| Net Income (Loss) · FY2026 | $-8M | |
| Cash and Cash Equivalents · FY2026 | $186M | +44% y/y |
| Free Cash Flow · FY2026 | $32M | |
| Food Safety Revenue · Food Safety · FY2026 | $641M | +1% y/y |
| Animal Safety Revenue · Animal Safety · FY2026 | $229M | -11% y/y |
| Adjusted EBITDA Margin · FY2026 | 20.4% | |
| Operating Cash Flow · FY2026 | $83M | |
| Total Debt · FY2026 | $794M | -11% y/y |
Guidance
FY2026 revenue guidance raised from $820-840M to $870.4M actual; FY2027 not explicitly guided
Revenue guidance raised significantly during FY2026; management tone positive on transformation and growth trajectory.
Risks flagged
Global trade uncertainty and tariffs
“the effects of global trade uncertainty and tariffs” · word for word
Transformation execution risk
“the Company’s ability to execute its transformation strategy” · word for word
Supply chain disruptions
“supply chain disruptions” · word for word
Integration and restructuring risk
“integration and restructuring activities” · word for word
Key employee retention risk
“the ability to attract and retain key employees” · word for word
7 Aug 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Board departure without explanation could signal governance instability or strategic misalignment.
“Resignation of director Thierry Bernard effective August 3, 2026.”
30 Jul 202610-KNeogen reported FY2026 revenue of $870.4M (-3% YoY) with improved operating loss and cash flow, driven by divestiture gain and cost reductions.earningsopen
Figures in the filing · each found in the filing text
| Total Revenues · FY2026 | $870M | -3% y/y |
| Food Safety Revenue · Food Safety · FY2026 | $641M | +1% y/y |
| Animal Safety Revenue · Animal Safety · FY2026 | $229M | -11% y/y |
| Gross Profit Margin · FY2026 | 46.9% | |
| Net Loss · FY2026 | $-8M | |
| Operating Cash Flow · FY2026 | $83M | +43% y/y |
| Cash and Cash Equivalents · 2026-05-31 | $186M | +44% y/y |
| Service Revenue · FY2026 | $102M | +5% y/y |
Risks flagged
Petrifilm manufacturing transition risk
“duplicative costs as we prepare to manufacture Petrifilm products internally” · word for word
Foreign exchange exposure
“A hypothetical 10% depreciation in foreign currency exchange rates relative to the U.S. dollar as of May 31, 2026 would result in an approximate decrease in reported revenue of $44.5 million” · word for word
High debt levels
“As of May 31, 2026, we had approximately $800.0 million of outstanding indebtedness” · word for word
30 Jul 20268-K · 2.02Neogen reports Q4 FY2026 revenue $225.3M, core growth 4.3%, adjusted EBITDA $45.4M (20.2% margin), provides FY2027 guidance; gross margin improved to 47.8% from 41.2% YoY.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2026 | $225M | -0% y/y |
| Revenue · FY2026 | $870M | -3% y/y |
| Gross Margin · Q4-2026 | 47.8% | |
| Adjusted EBITDA · Q4-2026 | $45M | +12% y/y |
| Adjusted EBITDA Margin · Q4-2026 | 20.2% | |
| Net Loss · Q4-2026 | $-11M | |
| Adjusted EPS · Q4-2026 | $0.09 | +80% y/y |
| Free Cash Flow · Q4-2026 | $26M | |
| Food Safety Revenue · Food Safety · Q4-2026 | $167M | +3% y/y |
| Animal Safety Revenue · Animal Safety · Q4-2026 | $59M | -8% y/y |
Guidance
FY2027 revenue and Adjusted EBITDA guidance provided; specific numbers not disclosed in excerpt.
Management provided FY2027 guidance with positive tone, citing momentum and disciplined execution.
Risks flagged
Animal Safety segment still declining YoY, though recovering sequentially.
“Animal Safety revenue -8.2% YoY; core growth only 0.5%.”
Rodent Control, Insect Control & Disinfectants revenue declined sharply in both segments.
“Food Safety rodent control -65.5% YoY; Animal Safety rodent control -22.3% YoY.”
9 Apr 202610-QNeogen reported Q3 FY2026 revenue of $211.2M, down 4.4% YoY, with gross margin declining 300 bps to 46.9% and net loss widening to $17.0M.earningsopen
Figures in the filing · each found in the filing text
| Total Revenues · Q3-2026 | $211M | -4% y/y |
| Gross Margin · Q3-2026 | 46.9% | |
| Net (Loss) Income · Q3-2026 | $-17M | +56% y/y |
| Operating Cash Flow · 9M-2026 | $53M | +27% y/y |
| Food Safety Revenue · Food Safety · Q3-2026 | $157M | +3% y/y |
| Animal Safety Revenue · Animal Safety · Q3-2026 | $55M | -20% y/y |
| Service Revenue · Q3-2026 | $25M | +2% y/y |
| International Revenue · Q3-2026 | $109M | +3% y/y |
| Capital Expenditures Estimate · FY2026 | $50M | |
| Cash and Cash Equivalents · 2026-02-28 | $160M |
Guidance
FY2026 capex estimate ~$50M; Petrifilm manufacturing inefficiencies expected to improve; supplier issues to impact into FY2027
Management expects continued improvement in Petrifilm manufacturing inefficiencies but anticipates supplier quality issues to persist into early FY2027. No formal revenue or EPS guidance provided.
Risks flagged
Supplier Quality and Manufacturing Issues
“in the third quarter of fiscal year 2026, we encountered a number of third-party supplier quality and manufacturing issues that detrimentally impacted the revenue in our Animal Safety segment. Some of these issues are related to manufacturing transitions at our suppliers associated with global tariffs.” · word for word
Tariff Exposure
“These have increased, and may continue to increase our costs on materials imported into the U.S. and have also increased costs and negatively impacted sales from our international locations, which primarily sell U.S. manufactured products.” · word for word
Integration and Manufacturing Transition Risks
“The decrease in margin was primarily due to volume decreases, higher inventory write-offs, and duplicative costs as we prepare to manufacture Petrifilm products internally.” · word for word
Consumer Demand Softness
“we continued to face economic headwinds, including softening consumer demand, elevated interest rates, and ongoing geopolitical tensions in certain regions, such as eastern Europe and the Middle East.” · word for word
9 Apr 20268-K · 2.02Revenue $211M (-4% y/y); Core Growth 0.1; Food Safety Revenue $157M (+3% y/y); Guidance: FY26 revenue outlook raised; Adjusted EBITDA guidance maintained.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2026 | $211M | -4% y/y |
| Core Growth · Q3-2026 | 0.1% | |
| Food Safety Revenue · Food Safety · Q3-2026 | $157M | +3% y/y |
| Food Safety Core Growth · Food Safety · Q3-2026 | 4.0% | |
| Animal Safety Revenue · Animal Safety · Q3-2026 | $55M | -20% y/y |
| Animal Safety Core Growth · Animal Safety · Q3-2026 | -8.7% | |
| Adjusted EBITDA · Q3-2026 | $48M | |
| Adjusted EBITDA Margin · Q3-2026 | 22.8% | |
| Adjusted Net Income · Q3-2026 | $19M | |
| Adjusted EPS · Q3-2026 | $0.09 |
Guidance
FY26 revenue outlook raised; Adjusted EBITDA guidance maintained.
Company raised FY26 revenue outlook due to Food Safety strength, but maintained Adjusted EBITDA guidance; management expressed confidence in strategic transformation.
Risks flagged
Animal Safety segment severely impacted by third-party supplier issues, causing 20.1% revenue decline.
“Animal Safety revenue -20.1% YoY; core -8.7% due to supplier challenges.”
Petrifilm manufacturing transition carries execution risk; any delays could impact FY27 guidance.
“Petrifilm transition on track but multi-quarter process; validation initiated on multiple SKUs.”
Tariff costs and inventory write-offs impacted gross margin in the quarter.
“Gross margin decrease primarily due to duplicative costs related to Petrifilm manufacturing transition with some impact from tariff costs and inventory write-offs.”
30 Mar 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Departure of key legal officer could create temporary gap in legal and administrative oversight.
“Chief Legal and Administrative Officer leaving effective March 31, 2026.”
8 Jan 20268-K · 2.02Revenue $225M (-3% y/y); Core Revenue Growth 2.9; Net Loss $-16M; Guidance: Revenue guidance raised to $845-855M (from $820-840M); Adjusted EBITDA raised to ~$175M (from $165-175M)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $225M | -3% y/y |
| Core Revenue Growth · Q2-2026 | 2.9% | |
| Net Loss · Q2-2026 | $-16M | |
| Adjusted Net Income · Q2-2026 | $23M | -7% y/y |
| Adjusted EBITDA · Q2-2026 | $49M | -5% y/y |
| Adjusted EBITDA Margin · Q2-2026 | 21.7% | |
| Gross Margin · Q2-2026 | 47.5% | |
| Food Safety Segment Revenue · Food Safety · Q2-2026 | $166M | +1% y/y |
| Animal Safety Segment Revenue · Animal Safety · Q2-2026 | $59M | -12% y/y |
| Cash and Cash Equivalents · Q2-2026 | $145M |
Guidance
Revenue guidance raised to $845-855M (from $820-840M); Adjusted EBITDA raised to ~$175M (from $165-175M)
Neogen raised FY2026 revenue and Adjusted EBITDA guidance, citing sequential improvement in core revenue growth and profitability, Petrifilm integration progress, and strategic transformation initiatives.
Risks flagged
Tariff costs and inventory write-offs pressuring gross margin
“Gross margin decrease primarily due to tariff costs, inventory write-offs and a negative impact from product mix.”
Animal Safety segment revenue decline continues
“Animal Safety segment revenues...decrease of 11.8%...core revenue increase of 0.1%.”
High debt level of $800M with moderate cash position
“total outstanding debt of $800.0 million...total cash and cash equivalents of $145.3 million” · word for word
8 Jan 202610-QNeogen reported Q2 FY2026 revenue of $224.7M, down 2.8% YoY, with gross margin declining 150 bps to 47.5% and net loss of $15.9M.earningsopen
Figures in the filing · each found in the filing text
| Total Revenues · Q2-2026 | $225M | -3% y/y |
| Gross Margin · Q2-2026 | 47.5% | |
| Net (Loss) Income · Q2-2026 | $-16M | -97% y/y |
| Operating Cash Flow · 6M-2026 | $30M | +36% y/y |
| Food Safety Revenue · Food Safety · Q2-2026 | $166M | +1% y/y |
| Animal Safety Revenue · Animal Safety · Q2-2026 | $59M | -12% y/y |
| Service Revenue · Q2-2026 | $26M | +8% y/y |
| International Revenue · Q2-2026 | $114M | -3% y/y |
| Capital Expenditures Estimate · FY2026 | $50M | |
| Cash and Cash Equivalents · 2025-11-30 | $145M |
Guidance
FY2026 capex estimate ~$50M; Petrifilm manufacturing inefficiencies expected to improve
Management expects continued improvement in Petrifilm manufacturing inefficiencies but no formal revenue or EPS guidance provided.
Risks flagged
Tariff Exposure
“These have and may continue to increase our costs on materials imported into the U.S. and also increase costs and negatively impact sales from our international locations, which primarily sell U.S. manufactured products.” · word for word
Integration and Manufacturing Transition Risks
“The decrease in margin was primarily due to higher manufacturing costs related to our sample collection product line, higher tariffs and inventory write-offs, and duplicative costs as we prepare to manufacture Petrifilm products internally.” · word for word
Consumer Demand Softness
“we continued to face economic headwinds, including softening consumer demand, elevated interest rates, and ongoing geopolitical tensions in certain regions.” · word for word
30 Oct 20258-K · 5.02, 8.01Reported the departure of a director or principal officer (CEO/CFO change); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Key executive transition risk as CFO departs and new CFO onboarded
“Appointment of new CFO following resignation of prior CFO/COO David Naemura.”
Neogen Corporation — questions
- What did Neogen Corporation file recently?
- 13 SEC filings in the last 12 months. Latest: 10-Q on 2026-10-07 — Neogen reported Q1 FY2027 revenue of $222.8M (+6.5% YoY) and gross margin improvement to 47.4%, but a net loss of $11.9M due to absence of prior year gain on sale.
Every figure on this page comes from Neogen Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.